Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Apotransferrin in β-thalassemia Intermedia
NCT03993613Phase 2Terminated
- Sponsor
- Prothya Biosolutions
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of apotransferrin in beta-thalassemia intermedia, sponsored by Prothya Biosolutions. Started Mar 2019; status: terminated.
02
Drugs
apotransferrin
03
Conditions
beta-thalassemia intermedia
Beyond the preview
Go deeper on NCT03993613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993613.